APP
ZNTL icon

Alpha Paradigm Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Alpha Paradigm Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,523
Closed -$719K – 692
2021
Q2 		$719K Buy
+13,523
New +$724K 0.27% 120

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alpha Paradigm Partners's ZNTL Position: Q3 2021 in Review

Alpha Paradigm Partners sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2021, closing a stake of 13,523 shares — an estimated $719K sold.

Alpha Paradigm Partners first reported a position in ZNTL in Q2 2021 and held it in 1 quarter. The position peaked at $719K in Q2 2021. 116 funds tracked by Wall St. Rank hold ZNTL as of Q3 2021.

  • Alpha Paradigm Partners reported no remaining Zentalis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Alpha Paradigm Partners sold 13,523 Zentalis Pharmaceuticals shares in Q3 2021, an estimated $719K.
  • Alpha Paradigm Partners first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Alpha Paradigm Partners's Zentalis Pharmaceuticals position peaked at $719K in Q2 2021.
  • 116 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2021.

Based on Alpha Paradigm Partners's 13F filing for Q3 2021, filed 15 Nov 2021.